Alrex ophthalmic suspension (loteprednol etabonate ophthalmic suspension) 0.2% is indicated for temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.1
Alrex contains a C-20 ester corticosteroid that covers many inflammatory mediators of the ocular allergic cascade.* Common signs and symptoms that are associated with inflamed seasonal allergic conjunctivitis include: itching, swelling, tearing, burning, redness, foreign-body sensation, and discomfort.2
*There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act in the manner described.
INDICATION AND USAGE
Alrex Ophthalmic Suspension is indicated for temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
IMPORTANT SAFETY INFORMATION
- Alrex is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of the ocular structures. Alrex is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.
- Prolonged use of Alrex is associated with several warnings and precautions, including glaucoma with optic nerve damage, defects in visual acuity, cataract formation, secondary ocular infections, exacerbation or prolongation of viral ocular infections (including herpes simplex), delay in wound healing and increase in bleb formation.
- If this product is used for 10 days or longer, intraocular pressure should be monitored. The initial prescription and renewal of the medication order beyond 14 days should be made by a physician only after examination of the patient with the aid of magnification. Fungal infections of the cornea may develop with prolonged use of corticosteroids.
- Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2% - 0.5%) in clinical studies included abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia.
Please click here(390.6 KB, PDF) to view the Alrex full Prescribing Information.
Alrex [package insert]. Tampa, FL: Bausch & Lomb Incorporated; 2013.
Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008;92(4):455-459.